Technology Bundle ID: TAB-2891

Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus

Request More Info
Licensing Contact:
Primary Inventors: 
Elizabeth Hunsperger (CDC)
Co-Inventors: 
Betty Poole-Smith (CDC), Tesfaye Taye (CDC)
Development Stage: 
Prototype
Development Status: 
  • In vitro data available
  • Prototype
Institute or Center: 
CDC

Following primary dengue virus (DENV) infection, non-structural protein 1 (NS1), a dengue-specific glycoprotein, is present in blood and is easily detected by various assays. However, for any infection thereafter (secondary infection), bioavailability of the glycoprotein greatly reduces sensitivity of DENV detection. Since secondary DENV infection is a risk factor for developing hemorrhagic fever, there is increasing need for more sensitive detection at this stage.

CDC investigators have developed a versatile method and monoclonal antibodies for detection of primary and secondary DENV infection. The antibodies specifically bind to heat-denatured NS1, allowing the addition of a heat denaturation step which greatly improves sensitivity of the detection assay. The assay was validated using actual dengue patient samples.

Applications:
  • Use of novel antibodies and methods for development of more sensitive diagnostics for primary and secondary DENV infection, including immunofluorescence assays, enzyme-linked immunosorbent assays, lateral flow assays and microsphere-based assay systems.
Advantages:
  • More sensitive DENV detection better for secondary infection.
  • Novel antibodies and methods can be applied to existing kits to increase sensitivity and ease of use.

Patents

PCT Application PCT/US2015/036939
Filed on 2015-06-22
US Application 62/014,982
Filed on 2014-06-20

Publications

Sharp TM, et al.
PMID 24452132

Updated

Nov 14, 2014

Data Source: 
tts